Back to search

Article

Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)

2022-09-21

Abstract excerpt

Background: Anti-tumour necrosis factor (TNF) drugs such as infliximab are associated with attenuated antibody responses after COVID-19 vaccination. It is unknown how infliximab impacts vaccine-induced serological responses against highly transmissible Omicron variants, which possess the ability to evade host immunity and are now the dominating variants causing current waves of infection.<br><br>Methods: CLARITY I...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b6d09897-a456-57d9-ae85-1400886760ea
DOI
10.2139/ssrn.4224500
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)DOI 10.2139/ssrn.4224500
COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or VedolizumabSemantic proximity
Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine DoseSemantic proximity
COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine DoseSemantic proximity
Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patientsSemantic proximity
COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional StudySemantic proximity
Serological response to COVID-19 vaccination in IBD patients receiving biologicsSemantic proximity
Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapiesSemantic proximity
Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccinationSemantic proximity
COVID-19 Vaccine Hesitancy Among Patients with Inflammatory Bowel Disease on Biologic Therapies; A cross-sectional studySemantic proximity
Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel DiseaseSemantic proximity
Long-term outcomes and neutralising antibody kinetics after Tixagevimab/Cilgavimab prophylaxis in haematological patients: a real-world cohort study in JapanSemantic proximity
Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel DiseaseSemantic proximity
Select a neighboring publication to make it the new centre.